EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners
EIT Pharma, Inc. (“EIT Pharma” or the “Company”), a biotechnology company focused on developing therapies for infectious diseases, today announced the successful close of an oversubscribed $35 million Series...

